DOP2022000018A - Análogos de relaxina y métodos para usarlos - Google Patents
Análogos de relaxina y métodos para usarlosInfo
- Publication number
- DOP2022000018A DOP2022000018A DO2022000018A DO2022000018A DOP2022000018A DO P2022000018 A DOP2022000018 A DO P2022000018A DO 2022000018 A DO2022000018 A DO 2022000018A DO 2022000018 A DO2022000018 A DO 2022000018A DO P2022000018 A DOP2022000018 A DO P2022000018A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- rln
- analogs
- disclosed
- methods
- relaxin
- Prior art date
Links
- 102000003743 Relaxin Human genes 0.000 title abstract 6
- 108090000103 Relaxin Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 101000869643 Homo sapiens Relaxin receptor 1 Proteins 0.000 abstract 1
- 102100032444 Relaxin receptor 1 Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se divulgan análogos de relaxina (RLN) que incluyen modificaciones que aumentan la semivida en comparación con la RLN humana nativa, que mantienen la selectividad para el receptor RXFP1 y que proporcionan estabilidad in vitro e in vivo para mejorar las propiedades de farmacología y reducir la inmunogenicidad. También se divulgan composiciones farmacéuticas que incluyen uno o más de los análogos de RLN descritos en la presente en un portador aceptable desde el punto de vista farmacéutico. También se divulgan métodos para elaborar y usar los análogos de RLN, en especial para tratar afecciones, enfermedades o trastornos cardiovasculares, pulmonares y/o renales.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962880968P | 2019-07-31 | 2019-07-31 | |
US202062970005P | 2020-02-04 | 2020-02-04 | |
PCT/US2020/044462 WO2021022139A1 (en) | 2019-07-31 | 2020-07-31 | Relaxin analogs and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2022000018A true DOP2022000018A (es) | 2022-03-15 |
Family
ID=72087312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2022000018A DOP2022000018A (es) | 2019-07-31 | 2022-01-27 | Análogos de relaxina y métodos para usarlos |
Country Status (18)
Country | Link |
---|---|
US (2) | US20220378931A1 (es) |
EP (2) | EP4004028A1 (es) |
JP (3) | JP2022542301A (es) |
KR (1) | KR20220031044A (es) |
CN (2) | CN114174348A (es) |
AU (1) | AU2020321977C1 (es) |
BR (1) | BR112022001448A2 (es) |
CA (2) | CA3145491A1 (es) |
CL (1) | CL2022000178A1 (es) |
CO (1) | CO2022000656A2 (es) |
CR (1) | CR20220021A (es) |
DO (1) | DOP2022000018A (es) |
EC (1) | ECSP22007726A (es) |
IL (1) | IL289464A (es) |
JO (1) | JOP20220023A1 (es) |
MX (1) | MX2022001136A (es) |
PE (1) | PE20220965A1 (es) |
WO (2) | WO2021022139A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3939605A1 (en) | 2016-12-09 | 2022-01-19 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
WO2019149782A1 (en) * | 2018-01-31 | 2019-08-08 | Sanofi | Modified lipidated relaxin b chain peptides and their therapeutic use |
EP4344738A3 (en) | 2018-06-29 | 2024-05-22 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
CN114846025A (zh) | 2019-12-19 | 2022-08-02 | 阿卡斯通生物科学公司 | 超长效胰岛素-Fc融合蛋白及其使用方法 |
US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
LT3972987T (lt) | 2020-04-10 | 2023-09-25 | Akston Biosciences Corporation | Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai |
US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
CN116802209A (zh) * | 2021-02-02 | 2023-09-22 | 伊莱利利公司 | 半衰期延长部分及其使用方法 |
US11667689B2 (en) | 2021-07-23 | 2023-06-06 | Akston Biosciences Corporation | Insulin-Fc fusion proteins and methods of use to treat cancer |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4835251A (en) | 1986-06-23 | 1989-05-30 | Genetech, Inc. | Method of chain combination |
DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
US5166191A (en) | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
JP3014764B2 (ja) | 1993-09-17 | 2000-02-28 | ノボ ノルディスク アクティーゼルスカブ | アシル化インスリン |
EP0741188A3 (en) | 1995-05-05 | 1999-07-14 | Eli Lilly And Company | Single chain insulin with high bioactivity |
EP1660531A2 (en) | 2003-08-05 | 2006-05-31 | Novo Nordisk A/S | Novel insulin derivatives |
JP5697831B2 (ja) | 2003-12-03 | 2015-04-08 | ノヴォ ノルディスク アー/エス | 単鎖インシュリン |
US20100216690A1 (en) | 2005-03-18 | 2010-08-26 | Novo Nordisk A/S | Pegylated Single-Chain Insulin |
US20090069216A1 (en) | 2006-02-21 | 2009-03-12 | Novo Nordisk A/S | Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof |
WO2007104736A2 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
WO2007104734A1 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
JP2009530243A (ja) | 2006-03-13 | 2009-08-27 | ノボ・ノルデイスク・エー/エス | アシル化単鎖インスリン |
JP2009530242A (ja) | 2006-03-13 | 2009-08-27 | ノボ・ノルデイスク・エー/エス | アシル化単鎖インスリン |
US7888913B1 (en) | 2009-09-08 | 2011-02-15 | Intermec Ip Corp. | Smart battery charger |
US20110172398A1 (en) * | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
US20110243943A1 (en) | 2010-04-02 | 2011-10-06 | Athena Discovery, Inc. | Treatment using relaxin-fusion proteins with extended in vivo half-lives |
US8940860B2 (en) | 2010-06-16 | 2015-01-27 | Indiana University Research And Technology Corporation | Single-chain insulin agonists exhibiting high activity at the insulin receptor |
CA2808596C (en) | 2010-08-17 | 2020-12-15 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
AU2011301146B2 (en) | 2010-09-08 | 2016-01-21 | Howard Florey Institute Of Experimental Physiology And Medicine | Single chain relaxin polypeptides |
US9382305B2 (en) | 2011-07-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
JP2014529293A (ja) | 2011-07-08 | 2014-11-06 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | レラキシンを放出する融合タンパク質およびその使用 |
WO2013177529A1 (en) | 2012-05-24 | 2013-11-28 | Angion Biomedica Corp. | Relaxin-like compounds and uses thereof |
CN103509118B (zh) | 2012-06-15 | 2016-03-23 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
ES2694418T3 (es) | 2012-11-05 | 2018-12-20 | Case Western Reserve University | Análogos de insulina de cadena sencilla de acción prolongada |
AR094147A1 (es) | 2012-12-27 | 2015-07-15 | Bayer Pharma Aktiengellschaft | Polipeptidos de fusion con actividad de relaxina y sus usos |
TWI755579B (zh) * | 2013-02-26 | 2022-02-21 | 南韓商韓美藥品股份有限公司 | 新穎胰島素類似物及其用途 |
MX2016005545A (es) * | 2013-11-07 | 2016-10-03 | Shanghai hengrui pharmaceutical co ltd | Analogo de la relaxina humana, composicion farmaceutica del mismo y aplicacion farmaceutica del mismo. |
WO2015067791A1 (en) | 2013-11-11 | 2015-05-14 | Ascendis Pharma Relaxin Division A/S | Relaxin prodrugs |
MA43289B1 (fr) | 2014-01-20 | 2019-12-31 | Hanmi Pharm Ind Co Ltd | Insuline à action prolongée et utilisation associée |
US10264071B2 (en) | 2014-03-31 | 2019-04-16 | Amazon Technologies, Inc. | Session management in distributed storage systems |
CA2945838C (en) | 2014-04-17 | 2022-08-16 | The Florey Institute Of Neuroscience And Mental Health | Modified relaxin b chain peptides |
JP6829928B2 (ja) | 2014-10-06 | 2021-02-17 | ケース ウェスタン リザーブ ユニバーシティCase Western Reserve University | 二相性単鎖インスリン類似体 |
MA41794A (fr) | 2015-03-18 | 2018-01-23 | The California Institute For Biomedical Res | Agents thérapeutiques modifiés et compositions associées |
AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
EP3344278A4 (en) | 2015-09-04 | 2019-01-23 | The California Institute for Biomedical Research | INSULIN-IMMUNOGLOBULIN FUSION PROTEINS |
JP2018531007A (ja) | 2015-09-24 | 2018-10-25 | ハンミ ファーマシューティカル カンパニー リミテッド | インスリンの製造方法 |
EP3387019B1 (en) * | 2015-12-09 | 2021-10-20 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
WO2017201340A2 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding relaxin |
CN110049997B (zh) * | 2016-12-07 | 2023-09-22 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合免疫球蛋白单可变结构域 |
JP2020505029A (ja) * | 2017-01-25 | 2020-02-20 | メディミューン,エルエルシー | リラキシン融合ポリペプチドおよびその使用 |
CN110637027A (zh) | 2017-02-08 | 2019-12-31 | 百时美施贵宝公司 | 包含药代动力学增强子的修饰的松弛素多肽及其用途 |
AR111122A1 (es) | 2017-03-07 | 2019-06-05 | Univ Case Western Reserve | Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro |
JOP20190273A1 (ar) | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
KR20190036956A (ko) | 2017-09-28 | 2019-04-05 | 한미약품 주식회사 | 지속형 단쇄 인슐린 아날로그 및 이의 결합체 |
WO2019106193A1 (en) * | 2017-12-01 | 2019-06-06 | University Of Copenhagen | Peptide hormone with one or more o-glycans |
-
2020
- 2020-07-31 CN CN202080054344.4A patent/CN114174348A/zh active Pending
- 2020-07-31 JP JP2022506024A patent/JP2022542301A/ja active Pending
- 2020-07-31 AU AU2020321977A patent/AU2020321977C1/en active Active
- 2020-07-31 WO PCT/US2020/044462 patent/WO2021022139A1/en active Application Filing
- 2020-07-31 CR CR20220021A patent/CR20220021A/es unknown
- 2020-07-31 EP EP20757182.9A patent/EP4004028A1/en active Pending
- 2020-07-31 CA CA3145491A patent/CA3145491A1/en active Pending
- 2020-07-31 PE PE2022000147A patent/PE20220965A1/es unknown
- 2020-07-31 US US17/632,173 patent/US20220378931A1/en active Pending
- 2020-07-31 US US17/632,107 patent/US20220275042A1/en active Pending
- 2020-07-31 CA CA3144989A patent/CA3144989A1/en active Pending
- 2020-07-31 WO PCT/US2020/044479 patent/WO2021022149A1/en unknown
- 2020-07-31 JP JP2022506200A patent/JP7270105B2/ja active Active
- 2020-07-31 KR KR1020227003397A patent/KR20220031044A/ko not_active Application Discontinuation
- 2020-07-31 BR BR112022001448A patent/BR112022001448A2/pt unknown
- 2020-07-31 MX MX2022001136A patent/MX2022001136A/es unknown
- 2020-07-31 CN CN202080054330.2A patent/CN114174347A/zh active Pending
- 2020-07-31 EP EP20757184.5A patent/EP4004027A1/en active Pending
- 2020-07-31 JO JOP/2022/0023A patent/JOP20220023A1/ar unknown
-
2021
- 2021-12-28 IL IL289464A patent/IL289464A/en unknown
-
2022
- 2022-01-24 CL CL2022000178A patent/CL2022000178A1/es unknown
- 2022-01-25 CO CONC2022/0000656A patent/CO2022000656A2/es unknown
- 2022-01-27 DO DO2022000018A patent/DOP2022000018A/es unknown
- 2022-01-31 EC ECSENADI20227726A patent/ECSP22007726A/es unknown
-
2023
- 2023-09-27 JP JP2023165484A patent/JP2024009827A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7270105B2 (ja) | 2023-05-09 |
JOP20220023A1 (ar) | 2023-01-30 |
CL2022000178A1 (es) | 2022-11-18 |
KR20220031044A (ko) | 2022-03-11 |
CR20220021A (es) | 2022-02-11 |
PE20220965A1 (es) | 2022-06-10 |
EP4004027A1 (en) | 2022-06-01 |
JP2022542301A (ja) | 2022-09-30 |
CA3144989A1 (en) | 2021-02-04 |
ECSP22007726A (es) | 2022-02-25 |
US20220378931A1 (en) | 2022-12-01 |
CN114174347A (zh) | 2022-03-11 |
WO2021022149A1 (en) | 2021-02-04 |
US20220275042A1 (en) | 2022-09-01 |
EP4004028A1 (en) | 2022-06-01 |
AU2020321977C1 (en) | 2024-04-18 |
CN114174348A (zh) | 2022-03-11 |
CO2022000656A2 (es) | 2022-01-28 |
CA3145491A1 (en) | 2021-02-04 |
AU2020321977A1 (en) | 2022-02-24 |
IL289464A (en) | 2022-02-01 |
AU2020321977B2 (en) | 2023-10-19 |
TW202120536A (zh) | 2021-06-01 |
BR112022001448A2 (pt) | 2022-05-17 |
MX2022001136A (es) | 2022-02-16 |
JP2022542980A (ja) | 2022-10-07 |
WO2021022139A1 (en) | 2021-02-04 |
JP2024009827A (ja) | 2024-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP22007726A (es) | Análogos de relaxina y métodos para usarlos | |
ECSP21027049A (es) | Inhibidores de la proteína tirosina fosfatasa | |
CL2021001073A1 (es) | Análogos de proteína tirosina-tirosina y métodos de uso de esta | |
NI201700032A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del higado graso no alcohólico | |
MX2021012756A (es) | Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este. | |
CL2019002810A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos. | |
UY35465A (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) | |
CL2019002297A1 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos. | |
UY33288A (es) | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico | |
CR20190208A (es) | Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y | |
CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
CO2021005915A2 (es) | Composiciones estables de semaglutida y usos de las mismas | |
AR103246A1 (es) | Derivados de fgf21 y sus usos | |
BR112017004223A2 (pt) | método para induzir a síntese de ficobiliproteínas | |
BR112021018707A2 (pt) | Formulações compreendendo melflufeno | |
MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
CL2021003273A1 (es) | Composición farmacéutica parenteral del agonista dual glp1/2 | |
ECSP20067968A (es) | Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos | |
ECSP21037191A (es) | Pirazoles como moduladores de la hemoglobina | |
BR112022002491A2 (pt) | Formulações de cbd e usos das mesmas | |
AR119473A1 (es) | Análogos de relaxina y métodos para usarlos | |
EA202190217A1 (ru) | Формы ивосидениба и фармацевтические композиции | |
ECSP17045054A (es) | Derivados de fumagilol | |
AR124616A1 (es) | Dextrometadona como tratamiento modificador de enfermedad para trastornos y enfermedades neuropsiquiátricas | |
CO2020012484A2 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") |